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Abstract: Dermatitis herpetiformis (DH) is an inflammatory cutaneous disease with a chronic 
relapsing course, pruritic polymorphic lesions, and typical histopathological and immunop-
athological findings. According to several evidences, DH is considered the specific cutaneous 
manifestation of celiac disease, and the most recent guidelines of celiac disease have stated 
that, in celiac patients with a proven DH, a duodenal biopsy is unnecessary for the diagnosis. 
In this review, the most recent data about the diagnosis and the management of DH have been 
reported and discussed. In particular, in patients with clinical and/or histopathological findings 
suggestive for DH, the finding of granular IgA deposits along the dermal–epidermal junc-
tion or at the papillary tips by direct immunofluorescence (DIF) assay, together with positive 
results for anti-tissue transglutaminase antibody testing, allows the diagnosis. Thereafter, a 
gluten-free diet should be started in association with drugs, such as dapsone, that are able to 
control the skin manifestations during the first phases of the diet. In conclusion, although DH 
is a rare autoimmune disease with specific immunopathological alterations at the skin level, its 
importance goes beyond the skin itself and may have a big impact on the general health status 
and the quality of life of the patients.
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Introduction
Dermatitis herpetiformis (DH) is an inflammatory cutaneous disease with a chronic 
relapsing course, pruritic polymorphic lesions, and typical histopathological and 
immunopathological findings.
According to several evidences, DH is considered the specific cutaneous manifesta-
tion of celiac disease (CD). In fact, both diseases occur in gluten-sensitive individuals, 
share the same HLA haplotypes (DQ2 and DQ8), and improve following the adminis-
tration of a gluten-free diet.1 Moreover, patients with DH show typical CD alterations 
at the small bowel biopsy (ranging from villous atrophy to augmented presence of 
intraepithelial lymphocytes [IELs]) almost in all the cases, as well as the generation 
of circulating autoantibodies to tissue transglutaminase (tTG).
DH is predominately a disorder of Caucasians,2 although Japanese cases are 
increasingly reported.3 The incidence of the disease was found to be 11.5 per 100,000 
in Scotland4 and ranging from 19.6 to 39.2 per 100,000 in Sweden.5 In a recent study 
from Finland, the prevalence of DH was found to be 75.3 per 100,000 (eight times 
lower than the prevalence of CD in that area), while the annual incidence was found 
to 3.5 per 100,000 over the period 1980–2009, showing a decrease in the last years.6
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DH usually presents in the fourth and fifth decades, although 
individuals of any age can be affected. In a recent study from 
our group investigating 159 patients with DH, approximately 
27% of the patients were below the age of 10, and 36% below 
the age of 20, showing that, at least in Italy, pediatric DH is 
more common than expected in other countries.7
In 2009, the guidelines for the management of patients 
with DH were published by our group.1 However, according 
to recent literature, several new findings have been reported 
about the clinical and immunopathological features of DH; 
moreover, the novel guidelines for the management of CD 
from the European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition (ESPGHAN) were developed in 
2012.8 Therefore, an update on the diagnosis and treatment 
of DH would be helpful to improve the care of the patients.
Accordingly, in the next paragraphs, the clinical and the 
immunopathological features that can help in the diagnosis of 
DH are reported. Moreover, the management of the disease, 
which is based both on a gluten-free diet and on medications 
that can help control DH in the inflammatory phases, as well 
as its follow-up are discussed.
Clinical features
DH usually presents with symmetrical, grouped polymor-
phic lesions consisting of erythema, urticarial plaques, and 
papules,2,9–11 involving the extensor surfaces of the knees, 
elbows, shoulders, buttocks, sacral region, neck, face, and 
scalp. By contrast, herpetiform vesicles, which reflect the 
name of the disease, may occur later or are often immediately 
excoriated, resulting in erosions, crusted papules, or areas of 
postinflammatory dyschromia, and are usually not seen in 
the patients. Itching of variable intensity and scratching and 
burning sensation immediately preceding the development 
of lesions are common.2,9–11
Together with these manifestations, several atypical 
presentations have been reported in patients with DH, 
including purpuric lesions resembling petechiae on hands 
and feet,12–20 leukocytoclastic vasculitis-like appearance,21 
palmo-plantar keratosis,22 wheals of chronic urticaria,23 and 
lesions mimicking prurigo pigmentosa.24 Interestingly, in 
some cases patients may show erythema or severe pruritus 
alone, making the diagnosis challenging.25 Finally, patients 
with DH may present the clinical manifestations associated 
with gastrointestinal malabsorption, although less frequently 
than in CD.
Clinically, the main differential diagnoses in children are 
atopic dermatitis, scabies, papular urticaria, and impetigo, 
whereas eczema, other autoimmune blistering diseases 
 (especially IgA linear disease and bullous pemphigoid), 
nodular prurigo, urticaria, and polymorphic erythema should 
be considered in adults.1
Histopathological findings
The typical histopathological findings in the lesional skin of 
patients with DH consist of subepidermal vesicles and blisters 
associated with accumulation of neutrophils at the papillary 
tips.2,10,11 Sometimes, eosinophils can be found within the 
inflammatory infiltrate,26 making difficult the differential 
diagnosis with bullous pemphigoid.
The histopathology of a DH skin lesion can be evocative, 
but it is not diagnostic, since other bullous diseases, includ-
ing linear IgA dermatosis, epidermolysis bullosa acquisita, 
and others may show similar findings.1,2,10 Moreover, as 
demonstrated by Warren and Cockerell,27 the histopathologic 
picture is unspecific in approximately 35%–40% of the cases, 
revealing only perivascular lymphocytic infiltrate and mini-
mal inflammation in dermal papillae. Thus, to achieve the 
diagnosis, histopathologic examination should be always per-
formed in combination with DIF of perilesional skin, which 
represent the gold standard for the diagnosis of DH.1,2
Direct immunofluorescence
As just stated, DIF of uninvolved skin collected in the perile-
sional site is the gold standard for the diagnosis of DH.1,2 Two 
specific patterns of DIF are possible: 1) granular deposits at 
the dermal papillae and 2) granular deposits along the base-
ment membrane. Sometimes, a combination of both patterns, 
consisting in granular IgA deposition along the basement 
membrane with accentuation at the papillary tips, may be 
present.1,2 Recently, a third pattern consisting of fibrillar 
IgA deposits mainly located at the papillary tips has been 
described.28 Such a pattern is often seen in Japanese patients 
with DH, where it is described in up to 50% of the cases.3
Other kinds of immune deposits that can be found by DIF 
are the presence of perivascular IgA deposits in the upper 
dermis, as well as of granular IgM or C3 deposits at the 
dermal–epidermal junction and/or at the dermal papillae.
DIF has a sensitivity and a specificity close to 100% for 
the diagnosis of DH. Moreover, according to the ESPGHAN 
guidelines for CD, a positive DIF in a patient with suspected 
DH allows for the diagnosis of CD without the need of 
duodenal biopsy.8 DIF should be performed on uninvolved 
perilesional skin, since in skin lesions IgA can be removed 
by inflammatory cells. Moreover, patients must be on normal 
diet, because IgA deposits can disappear from the skin in 
period of times variable from weeks to months in patients 
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on a gluten-free diet. If the patient is on a gluten-free diet, 
a normal gluten-containing diet should be administered and 
the biopsy taken after at least 1 month.
In the case of negative results for DIF in patients with a 
high clinical suspicion of DH, the site of the biopsy should 
be reconsidered and another specimen should be taken from 
uninvolved perilesional skin. Very rarely, cases of patients 
with DH showing negative DIF results are reported in the 
literature.29–31 In such cases, the combination of clinical, 
histopathological, and serological data, together with all the 
examination needed for CD, can help make the diagnosis.
Serologic analysis
Patients with DH usually show the specific antibodies that 
can be found in patients with CD. Among them, IgA anti-tTG 
antibodies are considered the most sensitive and specific ones 
and should be tested as the first-line serologic investigation in 
patients with a suspected DH. Some patients may have IgA 
deficiency; so the total serum IgA should be tested to exclude 
false-negative results from the serological investigation.
IgA anti-endomysium antibodies (EMAs), IgA and IgG 
anti-deamidated synthetic gliadin-derived peptides (DGP), 
and IgA anti-epidermal transglutaminase (eTG) antibodies 
are considered specific and sensitive serologic markers for 
DH. Finally, other kinds of antibodies are currently under 
investigation in both patients with DH and CD. The main 
features of the antibodies that can be detected in patients 
with DH are reported in what follows.
Anti-tTG antibodies
Anti-tTG antibodies belong to the IgA1 subclass and repre-
sent a good marker of intestinal damage and of gluten-free 
diet adherence in patients with the DH/CD spectrum.32 The 
commercially available ELISA (enzyme-linked immuno-
sorbent assay) kits have a sensitivity ranging from 47% to 
95% and a specificity higher than 90% for the diagnosis 
of DH.33–36
Since they are detected with a validated immunoenzy-
matic assay that is quite cheap and easy to perform, they are 
currently considered the most useful serological marker in 
celiac patients.
eMA
Even EMA belong to the IgA1 subclass, and are directed 
against primate smooth muscle reticular connective tissue. 
The detection of EMA is based on an indirect immuno-
fluorescence assay on monkey esophagus. EMA testing has 
shown a specificity close to 100% and a sensitivity ranging 
from 52% to 100% for the diagnosis of DH.33–37 As for anti-
tTG, EMA are usually absent in patients on a gluten-free 
diet and thus represent a useful diet-compliance marker in 
celiac patients.9–11,38 However, since it is more expensive, 
time-consuming, and operator-dependent than the anti-tTG 
ELISA,38 EMA testing should be performed only in doubt-
ful cases.
Anti-DGP antibodies
In patients with CD, anti-DGP antibodies show lower sensi-
tivity and specificity than anti-tTG and EMA.39,40 Their role 
as a useful marker of CD in patients below the age of 2, in 
whom the other antibodies are often absent, is still under 
debate.41–43 Few reports are present in the literature about 
anti-DGP antibodies in patients with DH, showing results 
similar to those with anti-tTG ones.44–46 Therefore, in clini-
cal practice, anti-DGP antibodies should be tested only in 
doubtful cases.
Anti-eTG antibodies
Recent evidence has demonstrated that patients with DH 
have antibodies directed against eTG, which is considered 
the specific antigen of DH.47 Anti-eTG antibodies show for 
DH a sensitivity ranging from 52% to 100%, and a specificity 
higher than 90%,46,48–50 thus giving results similar to those 
with anti-tTG antibodies.
Since the ELISA kit to detect anti-eTG antibodies is not 
widely available in all the laboratories, to date they are tested 
only for research purposes and not for the clinical manage-
ment of the patients.
Other antibodies
Other antibodies that are currently under investigation as 
markers for CD and/or DH are the anti-neoepitope tTG 
antibodies46 and the anti-GAF3X antibodies.51 Although they 
might be good markers for DH, further studies are required 
to confirm their usefulness as tools for the diagnosis of the 
disease.
HLA haplotypes testing
As in CD, virtually all patients with DH carry either HLA-
DQ2 (DQA1*05, DQB1*02) or HLADQ8 (DQB1*0302).1 
Thus, the presence of these alleles provides a sensitivity of 
close to 100% for DE and a very high negative predictive 
value for the disease (ie, if individuals lack the relevant 
disease-associated alleles, CD can be excluded). By contrast, 
since 30%–40% of the general population carry such HLA 
alleles, the specificity of such a test is very low.32
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Therefore, HLA testing, if negative, may be helpful in 
excluding the diagnosis of DH. It can also be helpful as a 
screening tool for patients with high risk for CD, including 
first-degree relatives of patients with CD.
Small bowel biopsy
As in CD, patients with DH show intestinal involvement that 
can be documented by histopathology in most cases. The 
features include partial-to-total villous atrophy, elongated 
crypts, decreased villus/crypt ratio, increased mitotic index 
in the crypts, increased IELs density, increased IEL mitotic 
index, infiltration of plasma cells, lymphocytes, mast cells, 
and eosinophils and basophils into the lamina propria.8 
However, in general, the histopathological alterations found 
in patients with DH are milder than those found in patients 
with CD.
According to the Marsh classification modified by 
 Oberhuber et al,52 the intestinal damage in CD patients can 
be divided into different stages, ranging from the normal 
mucosa to villous atrophy (Marsh III).
Since DH can be considered as CD of the skin, in a 
patient with a proven diagnosis of DH, duodenal biopsy 
is no longer required to confirm the diagnosis, as stated in 
recent guidelines.8 However, in doubtful DH cases (eg, with 
atypical clinical or immunopathological features), all the 
measures that are necessary to make a diagnosis of CD, 
including duodenal biopsy, should be performed. Moreover, 
duodenal biopsy should be performed in case of suspected 
gastrointestinal complications, including lymphoma.
Diagnostic algorithm
In patients with clinical and/or histopathological findings 
suggestive for DH, a biopsy of perilesional skin for DIF 
should be performed and serum samples should be collected 
to test anti-tTG antibodies (together with total IgA dosing). 
Then, basing on the evidences reported earlier, the diagnostic 
algorithm should be as follows (Figure 1):
1) In case of typical findings from DIF (ie, granular IgA 
deposits at the dermal–epidermal junction or at the papil-
lary tips) and of positive anti-tTG testing, the diagnosis of 
DH and, accordingly, of CD can be confirmed. Therefore, 
treatment and monitoring of DH should be managed (see 
text that follows).
2) In case of typical DIF results, but with negative anti-tTG 
antibodies, HLA DQ2/DQ8 testing is suggested. If nega-
tive, DH can be excluded, but if positive, patients should 
be further investigated. In particular, EMA and anti-DGP 
antibodies should be tested in order to exclude a previous 
false-negative result for anti-tTG antibodies. If EMA or 
anti-DGP antibodies are positive, DH can be confirmed. 
Clinical and histopathological features suggestive for DH
DIF in perilesional skin + IgA anti-tTG testing
DIF: +
Anti-tTG: +
DIF: +
Anti-tTG: −
HLA
DQ2/DQ8
DH excluded
DH
excluded
DH
confirmed
DH
confirmed
DH
confirmed
Duodenal
biopsy
Duodenal
biopsy
DH excluded Perform
another DIF
HLA
DQ2/DQ8
EMA,
DGP
DIF: −
Anti-tTG: +
DIF: −
Anti-tTG: −
−−
− + +
++
−
Figure 1 Diagnostic algorithm for patients with dermatitis herpetiformis.
Abbreviations: Anti-tTG, anti-tissue transglutaminase antibodies; DGP, anti-deamidated gliadin peptide antibodies; DH, dermatitis herpetiformis; DIF, direct immunofluorescence; 
eMA, anti-endomysium antibodies; HLA, human leukocyte antigen.
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If negative, the guidelines for the diagnosis of CD should 
be followed,8,53,54 including the implementation of duode-
nal biopsy, in order to confirm the intestinal involvement 
prior to starting a gluten-free diet.
3) In case of negative DIF and the presence of anti-tTG 
antibodies, HLA DQ2/DQ8 testing is suggested. If 
negative, DH can be excluded, but if positive, patients 
should be further investigated. First of all, a new skin 
biopsy of perilesional skin for DIF should be performed, 
in order to exclude false-negative results due to wrong 
sample collection in the previous skin biopsy. If the new 
DIF shows typical DH findings, the diagnosis can be 
confirmed. If DIF result is again negative, according to 
the guidelines for the diagnosis of CD, a duodenal biopsy 
is suggested.8,53,54
4) In case of negative results both for DIF and for anti-tTG 
testing, DH can be excluded and the clinical and histo-
pathological findings of the patients should be revised in 
order to achieve a different diagnosis.
Treatment
As previously stated, DH is considered the specific cutaneous 
manifestation of CD; therefore, a lifelong gluten-free diet is 
the first-choice treatment of the disease. However, in the first 
month after the diagnosis or in the inflammatory phases of the 
disease, in which a gluten-free diet alone would not be enough 
to control the symptoms, several drugs can be used for variable 
periods of time, including dapsone, sulfones or steroids.
Gluten-free diet
A strict gluten-free diet is the mainstay for treatment 
of the spectrum DH/CD. The level of gluten allowed 
is ,20 ppm (gluten-free); however, in some countries, prod-
ucts with ,100 ppm (very low gluten) are allowed.
Gluten-free diet is able to resolve both the gastrointestinal 
and the cutaneous manifestations, as well as to prevent the 
development of lymphomas and other diseases associated 
with gluten-induced enteropathy and malabsorption.
Gluten-free diet alleviates gastrointestinal symptoms in 
an average of 3–6 months, which is much more rapidly than 
what happens with the rash; in fact, it takes an average of 
1–2 years of a gluten-free diet for the complete resolution of 
the cutaneous lesions, which invariably recur within 12 weeks 
after the reintroduction of gluten. IgA antibodies may disap-
pear from the dermal–epidermal junction after many years 
of a strict gluten-free diet.55–59
Gluten is present in cereal species of the tribe Triticeae, 
which includes wheat, rye, and barley.56 Although in the 
past the basis of a gluten-free diet was the avoidance of all 
gluten-containing cereals, including wheat, barley, rye, and 
oats (mnemonic BROW), recently, some authors have dem-
onstrated that oats belonging to the Avenae tribe can be safely 
consumed by celiac patients.60–62 However, only oats known to 
be pure and not contaminated in any way with wheat, barley, 
or rye (which is the case of the majority of commercially 
available oats) can be safely consumed.2
As reviewed by Hischenhuber et al,63 evidence-based 
studies show that a diet including industrially purified gluten-
free wheat starch-based flours is safe for patients with DH/
CD spectrum and the small-intestinal mucosa heals and stays 
long-term morphologically normal.62
After following 133 DH patients, Garioch et al57 reported 
several advantages of a gluten-free diet, including a reduced 
need for medication to treat the cutaneous manifestations, the 
resolution of enteropathy, a general feeling of well-being, 
and a protective effect against development of lymphoma. 
Moreover, although further evidences are required, a gluten-
free diet might be helpful even in the prevention of the occur-
rence of DH/CD-related autoimmune disorders.
Recently, a few studies have suggested that DH can go 
into remission in up to 20% of the cases,64,65 and therefore, 
clinicians should continually reevaluate the need for a 
gluten-free diet for their patients with well-controlled DH.65 
However, since a gluten-free diet in patients with DH should 
not be considered a mere symptomatic approach to treat skin 
manifestation, but also the way to control and to prevent all 
the complications of CD, other studies are required to confirm 
whether the gluten-free diet can be safely discontinued.66 
Accordingly, lifelong commitment to a gluten-free diet is 
considered essential by gastroenterologists in CD and offers 
the patient a much better quality of life, avoidance of most 
complications, and an effective cure.67
Even though a gluten-free diet offers many benefits in 
the management of DH, in practice, it is not well adopted by 
many DH patients. In fact, it requires scrupulous monitor-
ing of all ingested foods, it is time-consuming, and socially 
restricting.56 Gluten-free products are not widely available 
and are more expensive than their gluten-containing counter-
parts; moreover, contamination with small amounts of gluten 
is possible.68 It has become evident that 20%–80% of patients 
with CD may continue to suffer from symptoms and still 
have a gluten-induced manifest mucosal lesion of Marsh II 
and III classes, and accordingly, some patients with DH still 
have skin manifestations, despite adherence to a gluten-free 
diet.62,69 Therefore, treatments alternative or integrative to the 
gluten-free diet in order to minimize cross-contamination 
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accidents typically occurring outside patients’ households 
would represent desirable interventions to minimize the risk 
of complications associated with prolonged gluten exposure 
in subjects affected by CD and DH.68
Dapsone
Although no reports from randomized controlled trials are 
present in the literature about its use, dapsone is considered 
a valid therapeutic option for patients with DH during the 6- 
to 24-month period until the gluten-free diet is effective.70–77 
The starting dose should be 50 mg/d in order to minimize the 
potential side effects. Then the dosage can be increased up 
to 200 mg/d until the disease is under control; in the main-
tenance phase, 0.5–1 mg/kg/d generally can control itching 
and the development of new skin lesions.71–78
As just reported, several side effects are associated with 
dapsone use. They are usually dose-dependent and more 
frequent in patients with comorbidities, such as anemia, 
cardiopulmonary disease, glucose-6-phosphate dehydroge-
nase deficiency.1,73
They are classified into toxic, including hemolytic anemia 
(that usually occurs within the first 2 weeks) and methemo-
globinemia, and idiosyncratic. Among the latter, dapsone 
hypersensitivity syndrome is considered the most severe 
and occurs within 2–6 weeks in approximately 5% of the 
patients, consisting of fever, photosensitivity, rash, malaise, 
lymphadenopathy, neurological effects, nephropathy, hypo-
thyroidism, gastrointestinal symptoms and liver involvement 
up to hepatic failure in some cases.75
Owing to these side effects, patients using dapsone 
should be carefully monitored. Before starting the therapy, 
complete blood count, glucose-6-phosphate dehydrogenase, 
methemoglobinemia, liver and renal functions, as well as 
urinalysis should be investigated. Then, patients should be 
reevaluated every week for the first month to monitor anemia, 
methemoglobinemia, and neuropathy symptoms. After the 
first months, complete blood count should be performed twice 
a month for the following 2 months and then every 3 months 
(together with liver and renal function testing).78
Sulfasalazine, sulfapyridine,  
and sulfamethoxypyridazine
If dapsone fails to control the symptoms or in case of adverse 
effects, sulfasalazine (1–2 g/d), sulfapyridine (2–4 g/d), and 
sulfamethoxypyridazine (0.25–1.5 g/d) can be valid alterna-
tives for the treatment of patients with DH.2,79,80
All the three drugs share similar adverse effects, con-
sisting of gastrointestinal upset (with nausea, anorexia, 
and vomiting), hypersensitivity drug reactions, hemolytic 
anemia, proteinuria, and crystalluria. Therefore, before 
starting the treatment, full blood count with differential and 
urine microscopy with urinalysis should be carried out. The 
same examination should be repeated monthly after the first 
3 months and thereafter every 6 months.
The enteric-coated forms of the drugs, which are cur-
rently available, can prevent the symptoms associated with 
the gastrointestinal upset.79,80
Other drugs
Other drugs can be used to control the skin symptoms in 
patients with DH. Among them, potent (betamethasone val-
erate or dipropionate) or very potent (clobetasol propionate) 
topical steroids are helpful in cases with localized disease 
to reduce pruritus and the appearance of new lesions.78 
 Accordingly, systemic steroids or antihistamines can control, 
at least in part, itching and burning sensation, although their 
effectiveness is considered quite low.78
Other drugs that have been shown to be effective in some 
reports are topical dapsone, immunosuppressors such as 
cyclosporin A or azathioprine, colchicine, heparin, tetracy-
clines, nicotinamide, mycophenolate, and rituximab.81–88
Finally, several new experimental approaches for the 
treatment of CD are currently under investigation, includ-
ing the use of engineered grains and inhibitory gliadin 
peptides, immunomodulatory strategies to prevent the 
development of an immune response against gluten, the cor-
rection of the intestinal barrier defect, and others (reviewed 
in Fasano et al68). As happens with a gluten-free diet, such 
approaches might be helpful even in the control of DH skin 
manifestations.
Follow-up
Since DH is associated with CD, patients should be moni-
tored following the recent guidelines for such a disease.8,53,54 
Patients with DH should be evaluated at regular intervals 
(6 months after diagnosis and then yearly) by a multidisci-
plinary team involving at least a physician and a dietitian. 
The purposes of these visits are to assess the compliance with 
the gluten-free diet and the presence of dyslipidemia, and to 
evaluate the possible development of intestinal malabsorption 
and/or celiac-related conditions, including other autoimmune 
diseases and complications such as refractory CD, ulcerative 
ileitis, celiac sprue, or lymphoma. Among the autoimmune or 
immune-mediated associated diseases, Hashimoto thyroidi-
tis, insulin-dependent diabetes mellitus, pernicious anemia, 
multiple sclerosis, Sjögren syndrome, lupus erythematous, 
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rheumatoid arthritis, vitiligo, and psoriasis are the most fre-
quently reported, and should be investigated in patients with 
familiar history or evocative clinical signs.87
Together with the visits, laboratory investigations, 
including immunological assessment, celiac-specific anti-
bodies, and evaluation of intestinal malabsorption, should 
be performed. It should be remarked that there are no clear 
guidelines as to the optimal means to monitor adherence to 
a gluten-free diet. In fact, serological investigations (ie, anti-
tTG or EMA) are considered to be sensitive for major, but 
not for minor, transient dietary indiscretions.40
Conclusion
In this review, the most recent data about the diagnosis and 
the management of DH have been reported and discussed. 
Although DH is a rare autoimmune disease with specific immu-
nopathological alterations at the skin level,89 its importance 
goes beyond the skin itself. In fact, DH is considered a specific 
manifestation of gluten-sensitive enteropathy, and the National 
Institute of Health90 as well as the most recent ESPGHAN 
guidelines8 stated that a duodenal biopsy is unnecessary for the 
diagnosis in celiac patients with a proven DH. Therefore, not to 
miss a diagnosis of DH would allow the prompt introduction 
of a gluten-free diet, to prevent all the complications that are 
associated with CD and to improve the general health status 
as well as the quality of life of the patients.
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